2011
DOI: 10.1016/j.ijrobp.2010.10.015
|View full text |Cite
|
Sign up to set email alerts
|

High-Dose-Rate Monotherapy: Safe and Effective Brachytherapy for Patients With Localized Prostate Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
94
0
3

Year Published

2013
2013
2021
2021

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 157 publications
(106 citation statements)
references
References 31 publications
9
94
0
3
Order By: Relevance
“…Arcangeli et al (16) published a report comparing 80 Gy (2 Gy/fraction) versus 62 Gy (3.1 Gy/fraction) and showed that the hypofractionated schedule is superior to the conventional fractionation in terms of freedom from biochemical failure rate with equivalent toxicity. This is also confirmed by studies of high dose rate brachytherapy (HDR BT) (17)(18)(19). Our outcomes are consistent with those that have resulted from HDR BT.…”
Section: Discussionsupporting
confidence: 89%
“…Arcangeli et al (16) published a report comparing 80 Gy (2 Gy/fraction) versus 62 Gy (3.1 Gy/fraction) and showed that the hypofractionated schedule is superior to the conventional fractionation in terms of freedom from biochemical failure rate with equivalent toxicity. This is also confirmed by studies of high dose rate brachytherapy (HDR BT) (17)(18)(19). Our outcomes are consistent with those that have resulted from HDR BT.…”
Section: Discussionsupporting
confidence: 89%
“…В настоящее время имеется порядка 10 достаточно крупных иссле-дований, посвященных оценке результатов лечения больных с помощью ВДБТ в режиме монотерапии. Средний срок наблюдения за пациентами составляет от 2,7 до 8 лет [35][36][37][38][39][40][41]. Наиболее длительные сроки на-блюдения (около 8 лет) провели калифорнийские ис-следователи D. J. Demanes и соавт.…”
Section: особенности проведения различных видов бтunclassified
“…Наиболее длительные сроки на-блюдения (около 8 лет) провели калифорнийские ис-следователи D. J. Demanes и соавт. [36]. При этом пока-затель выживаемости без признаков биохимического рецидива РПЖ у пациентов группы низкого и проме-жуточного риска составил 97 %.…”
Section: особенности проведения различных видов бтunclassified
“…105%). These dose constraints were developed through clinical experience as well as long-term followup of patients demonstrating low acute and long-term toxicity (19). The HG target was a modification of the WG target whereby the urethra was used to divide the volume into a left and right HG.…”
Section: Treatment Planningmentioning
confidence: 99%